IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced the recipients of its IFF Science Awards, recognizing Dr. Carles Lerín of Institut de Recerca Sant Joan de Déu in Barcelona, Spain, and Prof. Jan Maarten van Dijl of the University Medical Center Groningen in Groningen, Netherlands, for their outstanding contributions to the fields of human health, nutrition and antimicrobial research. The IFF Science Awards honor individuals for their...

Legora, the collaborative AI platform for lawyers, today announced the completion of a Series C round of $150 million at a $1.8 billion valuation, led by Bessemer Venture Partners, with significant investment from existing investors ICONIQ, General Catalyst, Redpoint Ventures, Benchmark, and Y Combinator, to accelerate its global expansion and growing product roadmap. The funding round takes place against a backdrop of rapidly increasing demand for Legora’s AI-powered platform for legal profe...

Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combina...

LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, today announced a second collaboration with Sanofi. This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties. Following the success of their first collabora...

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrolled at Dr. Vlada Groysman’s site in Birmingham, Alabama. This press release features multimedia. View the full release here: https://www.businesswire....